Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab maintenance after chemoradiation for high-risk locally advanced cervical cancer
2023-510268-11-00Phase 2Authorised
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dostarlimab in Cervical Cancer (CC) (2 arms), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoint: Progression-free survival. Planned start Mar 2024; status: authorised.
02
Drugs
dostarlimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2023-510268-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510268-11-00.